Compare RNST & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | VERA |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.2B |
| IPO Year | 1997 | 2021 |
| Metric | RNST | VERA |
|---|---|---|
| Price | $41.18 | $33.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $43.00 | ★ $81.30 |
| AVG Volume (30 Days) | 597.6K | ★ 969.5K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.72 | N/A |
| Revenue Next Year | $4.67 | $472.48 |
| P/E Ratio | $43.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.04 | $18.76 |
| 52 Week High | $42.11 | $56.05 |
| Indicator | RNST | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 39.09 |
| Support Level | $39.24 | $34.04 |
| Resistance Level | $42.11 | $42.77 |
| Average True Range (ATR) | 0.78 | 1.94 |
| MACD | 0.08 | -0.15 |
| Stochastic Oscillator | 92.35 | 17.80 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.